Hong Kong stocks are abnormal | Concept stocks of innovative drugs continue to rise, innovative drug payment reform accelerates, pharmaceutical companies are expected to continue to enter the period of performance harvest.

According to the Securities Times APP, concept stocks of innovative drugs continue to rise. As of the publication, Sinovac Biotech (02096.HK) rose by 8.02% to 10.64 Hong Kong dollars; Samson (01530.HK) rose by 7.58% to 18.17 Hong Kong dollars; Kangfang Bio (09926.HK) rose by 6.81% to 94.05 Hong Kong dollars; and Xinda Bio (01801) rose by 6.66% to 84.9 Hong Kong dollars.